Treatment options have changed considerably within the past years, especially with the advent of tyrosine-kinase-inhibitors (TKI) for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangement positive NSCLC, which comprises about 15% and 2% of NSCLC cases, respectively [2,3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.